Cat. No. Name Size Price Add Cart
KI0481CCT13769010 mg$272
CCT13769050 mg$1072

Chemical Characteristic

Product NameCCT137690
CAS No.1095382-05-0
Molecular Weight 551.48
FormulaC26H31BrN8O
Chemical Name3-[[4-[6-Bromo-2-[4-(4-methylpiperazin-1-yl)phenyl]-3H-imidazo[4,5-b]pyridin-7-yl]piperazin-1-yl]methyl]-5-methylisoxazole
Smileso1nc(cc1C)CN1CCN(CC1)c1c2c(ncc1Br)[nH]c(n2)c1ccc(cc1)N1CCN(CC1)C
Chemical Structure

Biological activities

CCT137690 is a potent and selective inhibitor of Aurora kinases. CCT137690 inhibits Aurora A, Aurora B and Aurora C with IC50 values of 15, 25 and 19 nM, respectively. CCT137690 inhibits the proliferation of SW620 colon carcinoma cell and A2780 ovarian cancer cell with GI50 of 0.3 and o.14 μM, respectively. CCT137690 also inhibit the phosphorylation of histone H3 and the major cytochrome P450 isoforms (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP3A4).[1] CCT137690 also efficiently inhibits histone H3 and transforming acidic coiled-coil 3 phosphorylation in HCT116 and HeLa cells. Furthermore, CCT137690 treatment of MYCN-amplified neuroblastoma cell lines inhibits cell proliferation and decreases MYCN protein expression. In a transgenic mouse model of neuroblastoma that overexpresses MYCN protein and is predisposed to spontaneous neuroblastoma formation, CCT137690 significantly inhibits tumor growth.[2] In SW620 colon carcinoma xenografts in vivo, CCT137690 treatment also inhibits the tumor growth with no observed toxicities as defined by body weight loss.[1]

Protocols

In vitro: CCT137690 is dissolved in DMSO.[3]

References

[1] Bavetsias V, et al. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J Med Chem. 2010, 53(14): 5213-5228.
[2] Faisal A, et al. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther. 2011, 10(11): 2115-2123.
[3] Moore AS, et al. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia. 2012, 26(7): 1462-1470.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.
KareBayTM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.